Effects of SGLT2 inhibition on cardiac remodeling and heart failure development in aortic stenosis rats.
4 affiliations
- 1Botucatu Medical School, UNESP, Botucatu, Brazil. [email protected].
- 2Department of Kinesiology and Sport Management, Texas A&M University, College Station, USA.
- 3Botucatu Medical School, UNESP, Botucatu, Brazil.
- 4Laboratory of Medical Investigation, Clinic Medical Department, University of Sao Paulo Medical School, Sao Paulo, Brazil.
Abstract
Aortic stenosis (AS) is increasingly prevalent in ageing populations, yet no pharmacological therapy has been shown to modify its progression to heart failure (HF). Sodium glucose cotransporter 2 (SGLT2) inhibitors improve outcomes in HF, but their effects in pressure overload-induced cardiac remodeling remain unclear. Here, we show that rats with long-term AS develop HF features, left ventricular dilation, and systolic and diastolic dysfunction, accompanied by increased oxidative stress, impaired antioxidant defenses, myocardial fibrosis, and transcriptional remodeling. Empagliflozin (10 mg/kg/day for 8 weeks) attenuated cardiac dysfunction and reduced HF features. At molecular level, empagliflozin prevented increase in lipid peroxidation, and decreased interstitial collagen deposition, while increasing glutathione peroxidase and matrix metalloproteinase-2 activity. Transcriptomic analysis identified 1,078 differentially expressed genes and revealed enrichment of pathways associated with extracellular matrix organization and signal transduction in AS. Empagliflozin predominantly regulated genes involved in cardiac contraction, mitochondrial membrane organization, apoptosis, and cell survival. Profibrotic and remodeling-associated genes were upregulated in AS, while empagliflozin induced a distinct transcriptional program associated with improved myocardial homeostasis. AS was associated with reduced activity of energy metabolism enzymes, which was not restored by empagliflozin. Collectively, these findings identify oxidative stress, extracellular matrix remodeling, and transcriptional reprogramming as mechanisms underlying cardiac dysfunction in AS. Empagliflozin mitigates cardiac remodeling and HF progression and modulates fibrosis and gene networks regulating cardiac function. These data highlight SGLT2 inhibition as a potential therapeutic strategy in pressure overload-induced heart failure.
Related
- Discovering gut microbiome signatures that predict adverse and reverse cardiac remodeling in preclinical heart failure
- Cardiac Reverse Remodeling and Clinical Outcomes Following Angiotensin Receptor‐Neprilysin Inhibitor Therapy in Heart Failure With Reduced Ejection Fraction
- A nurse-led digital nudging strategy to enhance home-based cardiac rehabilitation exercise adherence among patients with chronic heart failure: development of a complex intervention informed by the Medical Research Council framework.
- Tricuspid Stenosis Due to Cardiac Sarcoma
- The Hidden Danger of Aortic Stenosis-Exercise-Induced Cardiac Arrest in a Young Man with Bicuspid Aortic Valve.
BibTeX
@article{pagan2026effects,
title = {{Effects of SGLT2 inhibition on cardiac remodeling and heart failure development in aortic stenosis rats.}},
author = {Luana U Pagan and Mariana J Gomes and Mariana Gatto and Gustavo A F Mota and João Pedro G Oliveira and Felipe C Damatto and Lidiane M Souza and Eder A Rodrigues and Anna Clara C Santos and Gabriela H Tukiyama and Dijon H S Campos and Marcel Rodrigues Ferreira and Camila R Correa and Gilson M Murata and Bertha F Polegato and Marina P Okoshi and Katashi Okoshi},
journal = {Molecular biomedicine},
year = {2026},
month = oct,
doi = {10.1186/s43556-026-00642-x},
url = {https://europepmc.org/article/MED/42955596},
note = {CC BY},
}
RIS
TY - JOUR
TI - Effects of SGLT2 inhibition on cardiac remodeling and heart failure development in aortic stenosis rats.
AU - Luana U Pagan
AU - Mariana J Gomes
AU - Mariana Gatto
AU - Gustavo A F Mota
AU - João Pedro G Oliveira
AU - Felipe C Damatto
AU - Lidiane M Souza
AU - Eder A Rodrigues
AU - Anna Clara C Santos
AU - Gabriela H Tukiyama
AU - Dijon H S Campos
AU - Marcel Rodrigues Ferreira
AU - Camila R Correa
AU - Gilson M Murata
AU - Bertha F Polegato
AU - Marina P Okoshi
AU - Katashi Okoshi
PY - 2026
DA - 2026/10/28
JO - Molecular biomedicine
DO - 10.1186/s43556-026-00642-x
UR - https://europepmc.org/article/MED/42955596
AB - Aortic stenosis (AS) is increasingly prevalent in ageing populations, yet no pharmacological therapy has been shown to modify its progression to heart failure (HF). Sodium glucose cotransporter 2 (SGLT2) inhibitors improve outcomes in HF, but their effects in pressure overload-induced cardiac remodeling remain unclear. Here, we show that rats with long-term AS develop HF features, left ventricular dilation, and systolic and diastolic dysfunction, accompanied by increased oxidative stress, impaired antioxidant defenses, myocardial fibrosis, and transcriptional remodeling. Empagliflozin (10 mg/kg/day for 8 weeks) attenuated cardiac dysfunction and reduced HF features. At molecular level, empagliflozin prevented increase in lipid peroxidation, and decreased interstitial collagen deposition, while increasing glutathione peroxidase and matrix metalloproteinase-2 activity. Transcriptomic analysis identified 1,078 differentially expressed genes and revealed enrichment of pathways associated with extracellular matrix organization and signal transduction in AS. Empagliflozin predominantly regulated genes involved in cardiac contraction, mitochondrial membrane organization, apoptosis, and cell survival. Profibrotic and remodeling-associated genes were upregulated in AS, while empagliflozin induced a distinct transcriptional program associated with improved myocardial homeostasis. AS was associated with reduced activity of energy metabolism enzymes, which was not restored by empagliflozin. Collectively, these findings identify oxidative stress, extracellular matrix remodeling, and transcriptional reprogramming as mechanisms underlying cardiac dysfunction in AS. Empagliflozin mitigates cardiac remodeling and HF progression and modulates fibrosis and gene networks regulating cardiac function. These data highlight SGLT2 inhibition as a potential therapeutic strategy in pressure overload-induced heart failure.
SN - 2662-8651
ER -